北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy
作者: Qin, Ya-Zhen1; Xu, Lan-Ping1; Chen, Huan1; Jiang, Qian1; Wang, Yu1; Jiang, Hao1; Zhang, Xiao-Hui1; Han, Wei1; Chen, Yu-Hong1; Wang, Feng-Rong1; Wang, Jing-Zhi1; Zhu, Hong-Hu1; Liu, Yan-Rong1; Jiang, Bin1; Liu, Kai-Yan1; Huang, Xiao-Jun1,2
关键词: Clinical results ; myeloid leukemias and dysplasias ; prognostication
刊名: LEUKEMIA & LYMPHOMA
发表日期: 2015-11-02
DOI: 10.3109/10428194.2015.1032964
卷: 56, 期:11, 页:3116-3123
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: MINIMAL RESIDUAL DISEASE ; POLYMERASE-CHAIN-REACTION ; FRENCH AML INTERGROUP ; QUANTITATIVE RT-PCR ; C-KIT MUTATIONS ; RISK STRATIFICATION ; PROGNOSTIC VALUE ; MARROW-TRANSPLANTATION ; CANCER PROGRAM ; GROUP-B
英文摘要:

Eighty-six adult patients with inv(16) acute myeloid leukemia (AML) in first complete remission (CR1) were serially monitored for CBFB-MYH11 transcript levels during the early courses of chemotherapy. Fifty-seven and 29 of them received chemotherapy/autologous stem cell transplant (SCT) and allogeneic (allo-)SCT after second consolidation, respectively. For patients receiving chemotherapy/autologous SCT, the sole independent adverse prognostic factor for the cumulative incidence of relapse (CIR), disease-free survival (DFS) and overall survival (OS) was a CBFB-MYH11 level > 0.2% after course 2 consolidation (p = 0.003, 0.003 and 0.031), which was used to define a poor molecular response (MR). Allo-SCT significantly decreased the 3-year CIR and increased the DFS and OS of patients with a poor MR (p < 0.0001, 0.0001 and 0.045) but did not improve the outcome of patients with good MR (all p > 0.05) compared with chemotherapy/autologous SCT. Therefore, allo-SCT could improve the outcome of adult patients with inv(16) AML in CR1 with a poor MR during the early courses of chemotherapy.

语种: 英语
所属项目编号: Z141100000214011 ; 81170483
项目资助者: Beijing Municipal Science and Technology Program ; Nature Science Foundation of China
WOS记录号: WOS:000365520200019
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/63425
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
2.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China

Recommended Citation:
Qin, Ya-Zhen,Xu, Lan-Ping,Chen, Huan,et al. Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy[J]. LEUKEMIA &amp; LYMPHOMA,2015,56(11):3116-3123.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Qin, Ya-Zhen]'s Articles
[Xu, Lan-Ping]'s Articles
[Chen, Huan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Qin, Ya-Zhen]‘s Articles
[Xu, Lan-Ping]‘s Articles
[Chen, Huan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace